BioDuro & neoX Partner to Create Next Generation Antibody Discovery Platform

BioDuro and neoX join forces to pioneer a synthetic antibody discovery platform, integrating AI and high-throughput screening to expedite development of
April 28, 2020

Sundia’s SARS-CoV-2 3CLpro assay is ready to meet the challenges of COVID-19 pandemic

Sundia's Biology team launches a SARS-CoV-2 3CLPro assay to aid in anti-COVID-19 drug development, utilizing high-throughput screening for effective protease i
April 18, 2020

BioDuro Breaks Ground on 300,000 sq ft Facility in Jiangsu China

BioDuro expands its global footprint with a new 300,000 sq ft R&D facility in Jiangsu, China, bolstering drug development capabilities with 1,000 scientists
April 17, 2020

BioDuro Strengthens Senior Leadership of Global CMC Solutions Business Unit

SAN DIEGO, April 1, 2020 – BioDuro, LLC, a leading drug discovery and development services organization, announced today the appointment of two senior leadership positions to the Global CMC Solutions bus
April 01, 2020

Congratulations to HitGen for NTRK/ROS1 Inhibitor HG030 Approved for Clinical Trial

Congratulations to HitGen for their small-molecule tyrosine kinase inhibitor HG030 and tablets (CXHL2000004、CXHL2000003) has obtained IND approval from the CDE
April 01, 2020
Total 85 12...78910111213...1617
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all